Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL708236 | 0.85 | AGTR2 (0.66) | AGTR2AGTR1 | |
| SCHEMBL30194912 | 0.84 | AGTR2 (0.64) | AGTR2AGTR1 | |
| SCHEMBL29107870 | 0.83 | AGTR2 (0.46) | AGTR2AGTR1 | |
| SCHEMBL29107891 | 0.83 | AGTR2 (0.46) | AGTR2AGTR1 | |
| SCHEMBL707085 | 0.82 | AGTR2 (0.71) | AGTR2AGTR1 | |
| SCHEMBL3259789 | 0.80 | CYP11B1 (0.59) | — | |
| SCHEMBL29958677 | 0.80 | AGTR2 (0.47) | AGTR2AGTR1 | |
| SCHEMBL23831146 | 0.78 | AGTR2 (0.49) | AGTR2 | |
| Oxalic Acid SCHEMBL25295943 | 0.78 | AGTR2 (0.71) | AGTR2AGTR1 | |
| Oxalic Acid SCHEMBL30380649 | 0.78 | AGTR2 (0.71) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1529697-B | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB | 2010-09-22 | — | — | CN | disclosed |
| US-7652054-B2 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2010-01-26 | — | — | US | disclosed |
| EP-1395566-B1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| CN-1529697-A | Tricyclic compounds useful as angiotensin II agonists | ά�ƶ�ҩ�﹫˾ | 2004-09-15 | — | — | CN | disclosed |
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | AGTR1, AGTR2, NPY2R | AGTR2 2/4885AGTR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.